Stockhouse.com: Taking it to the street
Latest Broadcasts
T.GPR
Natural Resources
V.ARD
Technology-Internet
T.FR
Natural Resources
V.AIX
Natural Resources.
OMCY
Internet/Technology
V.KTN
Natural Resources, Metals and Mining
An excellent place to start your search for new investments!
add to favorites print

Angiotech Pharmaceuticals (ANP) shares up 29% Thursday

Shares of Angiotech Pharmaceuticals (TSX: T.ANP, Stock Forum) surged 29% to $2.09 Thursday, as the Vancouver-based company reported that its corporate partner, Boston Scientific Corporation (NYSE: BSX, Stock Forum) has received U.S. FDA approval to market its TAXUS Liberté Long Paclitaxel-Eluting Coronary Stent System, a drug-eluting stent designed for long lesions. 

The company says Boston Scientific plans to launch the product in the U.S. next month.  

Back in May, the company received FDA approval to market its TAXUS Liberté Atom Paclitaxel-Eluting Coronary Stent System. 

“Today's approval of the TAXUS Liberté Long Stent, along with the approval of the TAXUS Liberté Atom(TM) Stent in May, demonstrates the strength and breadth of the paclitaxel platform," said William Hunter, president and CEO of Angiotech. "We are pleased with the progress that Boston Scientific continues to make with TAXUS stents," he added.

On Angiotech’s website, the company says that its initial lead product, the TAXUS drug-eluting coronary stent - which was co-developed and is now sold by Boston Scientific Corporation - is implanted in over four million patients worldwide.

 
print
 
Stockhouse Conflict and Disclosure Policy:

Stockgroup Media Inc., owners and operators of Stockhouse.com, has established the following rules to ensure that there is no appearance of impropriety on the part of any Stockhouse Editorial writers ("Writers"). The content of Stockhouse Editorial articles (the "Articles") are the opinion of the Writer and any reliance on the content of these articles is at your sole risk. Our Writers are not registered investment advisors. You should not make any kind of investment decision in relation to Articles or stocks discussed in them without obtaining advice from a registered investment advisor.

Facts relied upon by our Writers are generally provided by the subject companies or gathered by our Writers from other public and/or private sources. These facts may be in error and if so, the opinions of our Writers may be materially different.

Writers may own, buy, or sell shares in public companies mentioned in their Articles, but in the Article they must prominently state their ownership position. Thus, a conflict may exist. Writers are not permitted to write Articles that attempt to benefit persons connected to the Writer, such as family or friends, except where disclosure is made in the same way as if the Writer him/herself owns stock.

Writers cannot solicit, accept, or agree to receive anything of value given or paid with the intent of influencing their Articles.

Stockhouse notifies each Writer about these rules, and we rely on the integrity of our Writers to ensure that our rules are followed.

 
 
 
 
 
Today's Feature  
 
Kootenay Gold Inc
Kootenay Gold Inc. is focused on the development of its wholly owned flagship “Promontorio Silver/Gold Project”. The results from Phase I & II drilling provided more than 15,000 m (57 holes) showing unique similarities to major deposits also located within Sierra Madre trend of Mexico (producing more than 520 million oz silver and 15 million oz gold within just the past 7 years)...